Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,095 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Lung Disease Clear all
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01437397
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
193
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 14, 2026, 5:25 AM EDT
Not listed Phase 3 Interventional

Ventilator Settings and Comfort

NCT01131390
View directory record Official record
Conditions
Obesity, Chronic Obstructive Pulmonary Disease
Interventions
Ventilator setting changes
Device
Lead sponsor
Bridgeport Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bridgeport, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 14, 2026, 5:25 AM EDT
Completed No phase listed Observational

Ancillary T Cell Based Studies in SPIROMICS

NCT02036190
View directory record Official record
Conditions
Smoke Induced Lung Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

NCT02512510
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 14, 2026, 5:25 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AMPLIFI: Adaptive Modulation of Plasticity Through Lactate and Fitness Interventions

NCT06950060
View directory record Official record
Conditions
Stroke, Chronic, Aging, Cognitive Decline, Motor Dysfunction, Neuroplasticity
Interventions
High intensity cycling, Low-intensity cycling, Health education session, Moderate Intensity Aerobic Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 5:25 AM EDT
Recruiting No phase listed Observational

The ROAM Research Study Therapy (LTOT) Version

NCT06810323
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 14, 2026, 5:25 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

NCT00064415
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol, Salmeterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
90
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00002625
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Lymphoma
Interventions
topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

NCT01111526
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Panobinostat (LBH589)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Home Air Purification for Eosinophilic COPD

NCT04252235
View directory record Official record
Conditions
COPD, Eosinophilia
Interventions
Air purifier, Sham air purifier
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Integrating Care After Exacerbation of COPD

NCT02021955
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
guideline treatment recommendations
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boise, Idaho • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

NCT05672355
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, COVID-19 Infection
Interventions
Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

NCT00832585
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Alefacept
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

NCT06003049
View directory record Official record
Conditions
COPD
Interventions
OnabotulinumtoxinA, Placebo
Drug · Other
Lead sponsor
RMW Testing
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

A Study for the Assessment of the Benefits of a Novel Mesh Nebulizer in the Treatment of Patients With Stable COPD

NCT03933462
View directory record Official record
Conditions
COPD
Interventions
InnoSpire Go, Jet Nebulizer
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Clairton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 14, 2026, 5:25 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

NCT02161744
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ADSCs administration
Biological
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

NCT05126563
View directory record Official record
Conditions
Post COVID-19 Syndrome
Interventions
HB-adMSCs (allogeneic), Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

NCT01862536
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tadalafil, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
West Los Angeles, California • Denver, Colorado • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Evaluation of a Portable Oxygen Concentrator During Ambulation for Patients Who Require Supplemental Oxygen (POC-LEAN)

NCT04107493
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Portable Oxygen Cylinder, Mobi
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 14, 2026, 5:25 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

NCT06944925
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BBT002, Placebo
Drug
Lead sponsor
Bambusa Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Natural Killer Cells and Bortezomib to Treat Cancer

NCT00720785
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
Interventions
Bortezomib, NK cells
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns

NCT00955487
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Inhaled Nitric Oxide (iNO), Nitrogen (placebo)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 72 Hours
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 14, 2026, 5:25 AM EDT